# Equine piroplasmosis status in the UK: an assessment of laboratory diagnostic submissions and techniques

Robert M Coultous,[1] Paul Phipps,[2] Charlie Dalley,[2] Jane Lewis,[2] Toni-Ann Hammond,[3] Brian R Shiels,[4] William Weir,[1] David G M Sutton[1]

Equine piroplasmosis (EP) has historically been of minor concern to UK equine practitioners, primarily due to a lack of competent tick vectors. However, increased detection of EP tick vector species in the UK has been reported recently. EP screening is not currently required for equine importation, and when combined with recent relaxations in movement regulations, there is an increased risk regarding disease incursion and establishment into the UK. This study evaluated the prevalence of EP by both serology and PCR among 1242 UK equine samples submitted for EP screening between February and December 2016 to the Animal and Plant Health Agency and the Animal Health Trust. Where information was available, 81.5 per cent of submissions were for the purpose of UK export testing, and less than 0.1 per cent for UK importation. Serological prevalence of EP was 8.0 per cent, and parasite DNA was found in 0.8 per cent of samples. A subsequent analysis of PCR sensitivity in archived clinical samples indicated that the proportion of PCR-positive animals is likely to be considerably higher. The authors conclude that the current threat imposed by UK carrier horses is not adequately monitored and further measures are required to improve national biosecurity and prevent endemic disease.

## Introduction

The UK has historically remained free from endemic equine piroplasmosis (EP), despite a near ubiquitous global presence.[1] Consequently, the disease has been of minimal concern to the UK equine practitioner and diagnostic testing has not been undertaken routinely, even in horses presenting with classical clinical signs such as haemolytic anaemia.

The basic pathology of EP together with the life cycle of its causative pathogens, *Theileria equi* and *Babesia caballi*, are well described in the literature.[1–3] Following inoculation by an infected tick vector, the protozoan parasite invades host erythrocytes, with additional invasion of host leucocytes in the case of *T equi*. The parasite replicates in the equine erythrocytes leading to rupture of the infected cell. This releases parasite merozoites into the circulation, which further invade and replicate within erythrocytes, perpetuating the infection. Within the tick host, transmission of *T equi* is through the transtadial route, while for *B caballi* transtadial and transovarian transmission both occur.[3] The clinical presentation of infection with one or both of these parasites is similar. Acute cases typically present with anaemia, pyrexia, lethargy, dehydration and anorexia with death occurring in severe or neglected cases.[1–3] In chronic disease, clinical signs are less severe, with animals displaying variable anaemia, malaise, anorexia, weight loss and reduced performance.[1–3] Infection with *T equi* has been detrimentally associated with athletic performance[4] and has a significant impact on the racing industry of endemic areas.[5] An association also has been claimed between EP and reduced fertility and abortion, with a reported 11 per cent of South African thoroughbred abortions being attributed to *T equi* infection.[6]

Importantly, the insidious nature of chronic and subclinical forms of the disease can lead to the creation of a latent carrier state that is particularly common in endemic regions. This has important implications for biosecurity. It is reported that *B caballi* carrier status is self-limiting with clearance achieved four

Veterinary Record (2018) doi: 10.1136/vr.104855

[1]School of Veterinary Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK
[2]Animal and Plant Health Agency, Addlestone, Surrey, UK
[3]Diagnostic Laboratory Services, Animal Health Trust, Newmarket, Suffolk, UK
[4]Institute of Biodiversity Animal Health and Comparative Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK

E-mail for correspondence: r.coultous.1@research.gla.ac.uk

Provenance and peer review Not commissioned; externally peer reviewed.

Received January 8, 2018
Revised August 8, 2018
Accepted October 19, 2018

years postinfection,[7] but this may be due to infection entering a latent stage.[1] Clearance of *B caballi* infection can been achieved through treatment with imidocarb dipropionate.[8] *T equi* carrier status is thought to be lifelong and can be maintained despite medical treatment.[9] The unmonitored importation of these carrier animals to different regions of the UK, compounded by a lack of tick control and prolonged co-grazing and mixing with naïve individuals, presents a potential means by which the infection could become established in the UK.

Although EP seropositive equids have been imported and present in the UK for many years, the lack of endemic EP in the British Isles has historically been attributed to a small and geographically limited vector tick population.[10] Up to 33 tick species have been identified as known or potential vectors for EP,[11] but *Dermacentor reticulatus* is the only confirmed EP vector species currently established in the UK. *D reticulatus* populations were thought to be limited to areas in western Wales and Devon; however, recent studies have documented geographical expansion of the species, with recognised populations now present in Essex.[12] The epidemiological importance of these new *D reticulatus* vector populations in the transmission of tickborne disease was highlighted in a recent canine piroplasmosis outbreak in the Essex area.[13]

EP has also been moving geographically closer to the UK in recent years, with an isolated *T equi* outbreak in Ireland in 2009,[14] autochthonous cases of both *T equi* and *B caballi* reported in Holland in 2011[15] and evidence of both parasites being well established in the Camargue of France.[16] When combined with current policies mitigating restrictions of certain equine movements, such as the Tripartite Agreement of 2014[17] and the proposed High Health High Performance (HHP) scheme,[18] the threat of EP to the resident UK horse population is becoming of increasing concern.

The latest World Organisation for Animal Health (OIE) status of EP in the UK (July–December 2017) is 'infection/infestation in domestic animals', and 'disease absent in wild animals'.[19] This reflects the presence of imported EP seropositive equids, with the absence of any autochthonous cases of endemic disease.

Currently, EP is not reportable or notifiable in the UK and imported animals are not tested routinely, despite the fact that seropositive chronic carrier horses are known to act as reservoirs of parasite infection for suitable sympatric tick species if present.[20] Serological testing in the UK is largely restricted to animals being exported to disease-free countries with compulsory import screening, such as the USA, Australia and Japan, where the disease is notifiable and controlled.

It is useful to consider the diagnostic tests presently available for EP screening. Current OIE guidelines recommend the indirect fluorescent antibody test (IFAT) and the competitive ELISA (cELISA) as the screening tests for international trade,[21] and the older complement fixation test (CFT) is still available and used commercially. Although sensitive, serological testing such as the cELISA does not reflect level of parasitaemia or provide information on the likelihood of onward transmission to feeding ticks, since antibodies persist for many months after apparent clearance of infection.[22] PCR methods and, specifically, nested PCR are considered to be the best means of establishing parasite burden in equids.[3] Despite the description of many PCR protocols in the literature, a commercial PCR screening assay for EP is not readily available to UK practitioners.

The main aim of this pilot study was to investigate the potential risk posed by seropositive horses resident in the UK, using follow-up nested PCR to determine animals with a parasite burden. A nested PCR protocol was developed and validated in-house using known positive field specimens. Results from UK diagnostic submissions for EP serology were also collated to facilitate estimation of the proportion of this sampled population that was serologically and PCR positive, therefore presenting a potential transmission risk to feeding tick species.

## Materials and methods

This prospective study used routine samples submitted by UK practitioners for EP serology testing at the Animal and Plant Health Agency (APHA) and the Animal Health Trust (AHT), between February and December 2016. Serological testing performed comprised CFT, IFAT and cELISA either singularly or in combination as requested by the submitting veterinary surgeon. The CFT, which was only available at the APHA, was performed in accordance with OIE standards using an in-house protocol. The APHA also performed IFAT assays using an in-house protocol in accordance with OIE standards; titres ≥1/80 were reported as positive. IFATs requested on AHT submitted samples were performed at the APHA, although the results have been associated with the AHT for data consistency (table 1). For cELISA testing, both the AHT and APHA used commercially available kits (*B caballi* 273–2 and *B equi* 274–2, VMRD, USA), with a result of ≥40 per cent reported as positive.

Following EP serological screening, all samples from both institutes were then forwarded to the University of Glasgow as anonymised clotted equine blood samples. They were then subjected to nested PCR, allowing subsequent comparison to the serological test results supplied by each laboratory. As the samples were submitted for the primary purpose of serology testing, only clotted blood was available for PCR screening.

For DNA extraction, 200 µl of clotted blood was mechanically agitated then enzymatically digested with proteinase K before extraction with the QIAamp DNA Mini Kit (Qiagen), using the manufacturer's recommended protocol. A total of 1211 samples were screened by nested PCR with a modified *Babesia/*

**Table 1** Breakdown by test type of EP-positive results from samples screened between February and December 2016

| | No. of samples | *T equi* serology (no. of positives/ total no. of tests) | | | | | *T equi* PCR | *B caballi* serology (no. of positives/ total no. of tests) | | | | | *B caballi* PCR |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| | | CFT | IFAT | cELISA | Total unique seropositives | | | CFT | IFAT | cELISA | Total unique seropositives | | |
| APHA | 1097 | 31/482 | 39/502 | 9/562 | 66/1050 | **6.3%** | 7/1066 | 17/479 | 33/504 | 2/563 | 49/1049 | **4.7%** | 0/1066 |
| AHT | 145 | NA | 4/9 | 4/145 | 4/145 | **2.8%** | 3/145 | NA | 1/9 | 2/145 | 3/145 | **2.1%** | 0/145 |
| Total | 1242 | **6.4%** | **8.4%** | **1.8%** | **5.9%** | | **0.8%** | **3.5%** | **6.6%** | **0.6%** | **4.4%** | | **0%** |

The results are listed by submitting organisation and test type. As some samples were found to be positive by multiple serological methods, the 'total unique seropositives' columns show the number of discrete positive samples for each species. Summary percentages for the relevant rows and columns are highlighted in bold.
AHT, Animal Health Trust; APHA, Animal and Plant Health Agency; *B caballi*, *Babesia caballi*; cELISA, competitive ELISA; CFT, complement fixation test; IFAT, indirect fluorescent antibody test; NA, not available; *T equi*, *Theileria equi*.

*Theileria* 18S SSU rRNA catch-all primer set, with outer primers[23] and inner primers[24] as described previously. These primers were reported to effectively detect a range of *Theileria/Babesia* species, including *T equi* and *B caballi*.[23] Before sample screening, the reaction conditions were optimised in-house with known EP-positive samples from Morocco, Gambia and Oman. Reaction conditions were an initial denaturation at 94°C for 5 minutes, followed by 30 cycles of 94°C for 45 seconds, with annealing at 67°C (external primers) or 57°C (internal primers) for 60 seconds, elongation at 72°C for 60 seconds and with a final extension at 72°C for 5 minutes. A 1:10 dilution of the primary reaction product was used as a template for the secondary reaction. The final product was visualised on a 1 per cent agarose electrophoresis gel. The PCR product was purified (QIAquick PCR Purification Kit, Qiagen) before Sanger DNA sequencing (Eurofins Genomics, Germany).

Sequences were subject to Basic Local Alignment Search Tool (BLAST) comparison (https://blast.ncbi.nlm.nih.gov/) with the non-redundant National Center for Biotechnology Information (NCBI) database to achieve species identification.

In each case, the result of the nested PCR was then compared with the EP serological test result as supplied by the original laboratory. Although all data were anonymised, and information about sampled animals was unavailable, the reason for EP serological test submission was known for the majority of specimens. Additionally, an acute case of piroplasmosis was confirmed during the study period, seen in a horse previously imported but now resident in the UK. Samples from this horse were used to compare the effect of coagulated and anticoagulated blood samples on nested PCR performance.

**Table 2** Reason for sample submission as noted by the submitting veterinary surgeon

| | Reason for EP testing | | | |
|---|---|---|---|---|
| | Import | Export | Other | Unknown |
| APHA | 1/1097 | 894/1097 | 189/1097 | 13/1097 |
| AHT | NA | NA | NA | 145/145 |

Most samples were submitted before intended export, highlighting that some countries require EP serology status to be determined before granting an importation licence. Notably, only one sample was specifically submitted to determine EP serological status at time of importation to the UK.
AHT, Animal Health Trust; APHA, Animal and Plant Health Agency; EP, equine piroplasmosis; NA, not available.

## Results

Serological test results and nested PCR results from the full 1, 242 UK laboratory EP submissions are presented in table 1. In summary, 5.9 per cent of samples submitted during the study period were serologically positive for *T equi* (n=70), and 4.4 per cent serologically positive for *B caballi* (n=52). Overall, EP seroprevalence was 8.0 per cent (n=96), with 27.1 per cent of these (n=26) being seropositive for both parasites. *T equi* parasite DNA was detected in 0.8 per cent (n=10) of the samples from these laboratory submissions. Sanger sequencing revealed that all nucleotide sequences detected had 97 per cent to 100 per cent identity to the relevant section of the 18S SSU rRNA gene of *T equi*. *B caballi* DNA was not detected in any sample.

The purpose of EP serology as stated on the submission form, and where permitted without breach of data confidentiality, is summarised in table 2. Testing before potential export is highlighted as the predominant reason (81.5 per cent of submissions), with only a single animal for UK importation being tested. It is unknown what proportion of seropositive horses in the present dataset had previously been imported to the UK. Specific data regarding the testing purposes for the 'other' category were not available.

In order to evaluate the sensitivity of EP serology, a comparison was made between those animals positive on nested PCR and serological status (table 3). Only 4 of the 10 samples identified to have parasite DNA present were found to be seropositive, with variations between cELISA, CFT and IFAT test results. It was not possible to infer statistical agreement between the different test types, as not all samples were subjected to each test.

The effect of sample submission type (coagulated vs anticoagulated EDTA blood) on PCR test results is demonstrated in figure 1, with samples from a confirmed UK case of EP submitted to the study. The affected horse (L1) in this case was imported several months previously and had developed clinical signs of anaemia and pyrexia, consistent with acute piroplasmosis. After positive cELISA and IFAT serology for EP from AHT, a blood sample was collected for PCR analysis.

**Table 3** Serological data for samples found to be positive by nested PCR during the study

| Samples positive by nested PCR | | | | | | | |
|---|---|---|---|---|---|---|---|
| ID | Organisation | CFT (*T equi*) | IFAT (*T equi*) | cELISA (*T equi*) | CFT (*B caballi*) | IFAT (*B caballi*) | cELISA (*B caballi*) |
| VLA12 | APHA | NA | Negative | NA | NA | Negative | NA |
| VLA14 | APHA | NA | Negative | NA | NA | Negative | NA |
| VLA15 | APHA | NA | Negative | NA | NA | Negative | NA |
| VLA255 | APHA | NA | ***Positive*** | NA | NA | ***Positive*** | NA |
| VLA265 | APHA | ***Positive*** | ***Positive*** | ***Positive*** | Negative | NA | Negative |
| VLA269 | APHA | NA | NA | Negative | NA | NA | Negative |
| VLA761 | APHA | ***Positive*** | Negative | ***Positive*** | ***Positive*** | Negative | Negative |
| AHT18 | AHT | NA | Negative | Negative | NA | Negative | Negative |
| AHT21 | AHT | NA | Negative | Negative | NA | Negative | Negative |
| L1 | AHT | NA | ***Positive*** | ***Positive*** | NA | Negative | Negative |

These samples were all positive for *T equi* and negative for *B caballi* on sequencing of the PCR product.
AHT, Animal Health Trust; APHA, Animal and Plant Health Agency; *B caballi, Babesia caballi*; cELISA, competitive ELISA; CFT, complement fixation test; IFAT, indirect fluorescent antibody test; NA, not available; *T equi, Theileria equi*.

Importantly, both a clotted and an anticoagulated (EDTA) jugular blood sample were collected at the same time and stored identically before submission. DNA extraction and nested PCR EP testing were performed concurrently and in triplicate on the submitted samples, and the results compared. The coagulated sample produced negative results in each case, while all three of the anticoagulated sample replicates produced a strong band that was subsequently sequenced and confirmed to be *T equi* in origin.

## Discussion

Within the 1242 samples submitted to the UK diagnostic services during the period February to December 2016 from horses resident in the UK, the overall seroprevalence of EP was 8.0 per cent. Although there is sparse information regarding EP seroprevalence in northern Europe, this is in line with similar datasets from Holland[15] and Switzerland[25] with 4 per cent and 7.3 per cent seroprevalence reported in these countries, respectively. Additional PCR-RLB performed by Butler and others[15] on EDTA blood detected *T equi* DNA in 1.6 per cent of samples and did not detect any *B caballi* DNA. However, this is not directly comparable to the current study's *T equi* DNA detection rate of 0.8 per cent and absence of detectable *B caballi* DNA, as the use of EDTA samples by Butler and others[15] may have provided greater sensitivity. Additionally, the sampled equine populations are not directly comparable between these and the current study. Butler and others[15] performed a cross-sectional study of 300 horses known to have been resident in the same location within Holland for at least one year. Sigg and others[25] reported that of their 689 sampled animals, 459 (66.6 per cent) were imported (having been brought to Switzerland up to five years before testing) and all of those had arrived from a European country. Seroprevalence was 8.5 per cent in these imported horses versus 4.8 per cent in indigenous horses.[25] In both studies, the previous movement history was limited or absent, making the geographical source of infection unclear. No geographical data or previous travel history was available for the current study samples due to data confidentiality.




**Figure 1** An electrophoresis gel showing the final PCR product from sample L1. The expected fragment length for Theileria equi was 433 bp. Template DNA was extracted from clotted blood samples (C1–C3) and from EDTA samples (A1–A3). Controls using DNA extracted from known equine piroplasmosis (EP) positive (P) and EP negative (N) horse blood are shown together with a 100 bp ladder (L).

Within the set of seropositive samples identified in this study, 27.1 per cent were found to be positive for both *T equi* and *B caballi*. This may be representative of exposure or infection by both parasites or serological false-positives[26]; cross-reactivity with *B caballi* has been noted at low titres with CFT and IFAT using serum from experimental *T equi* infections.[27] Due to a lack of further sampling and the absence of *B caballi* identification by PCR, further investigation of this finding is beyond the scope of this study.

Discrepancies between IFAT, cELISA and nested PCR results have been reported in experimental infection,[9] and this was noted in the present study. The discrepancies encountered were:

i) *Serologically negative, PCR-positive samples*. It is shown in table 3 that 6 of the 10 samples where *T equi* DNA was detected had negative serology results. Conventional logic would suggest that a detectable level of parasite DNA should promote a detectable immune response. The absence of seroconversion in the presence of parasite DNA could either be due to an early stage of infection or a fluctuating parasitaemia, where samples were taken at a time of parasite proliferation but before the rise of a detectable antibody titre. This anomaly

has been noted in the early course of experimental infection,[9] and there is indication that CFT may be more sensitive than other serological methods in these early stages of infection.[28] Disease recrudescence in EP has been noted to occur at times of increased stress and immunosuppression, such as may occur with increased handling, transport, co-infection and even lactation.[29] This phenomenon results in parasitic multiplication and the development of clinical signs in previously disease-free carrier animals. While recent movement may have resulted in parasite recrudescence in a proportion of the animals in this study, it is unlikely that all of them would have been free from detectable levels of antibodies because once established as carriers, animals seroconvert to EP.[9]

The discrepancy between test modalities may have resulted also from the intrinsic limitations of the serological testing. Serological tests can give false-negative results[26] and this incongruity has been observed in previous studies. One example is a recent Venezuelan study which found *T equi* to have a much higher PCR prevalence (61.8 per cent) than seroprevalence (14.0 per cent).[30] Additionally, Bhoora and others[31] postulated that genetic variation of the equine merozoite antigen-1 (EMA-1), on which the cELISA used by APHA and AHT is based, may have prevented the detection of some South African strains of *T equi* using this diagnostic technique.

ii) *High-titre serologically positive, PCR-negative results*. It was anticipated that a high serological titre would be associated with the presence of circulating parasite DNA and a positive PCR result. However, this was not seen in 15 high-titre (≥1/640) IFAT-positive samples that were evaluated (data not shown). Titre values for the cELISA were not available. A potential reason for this became evident following a private sample submission to the project from an imported horse (L1). This horse was undergoing veterinary evaluation following presentation with acute anaemia and pyrexia. Tested in triplicate, figure 1 shows that template DNA derived from EDTA blood samples provided clear positive bands, while the clotted blood samples were consistently negative. The reasons for this may include the degradation or reduction of available parasite DNA within the clotted samples and transfer of inhibitors during DNA extraction. Regardless of the exact cause, this clearly demonstrates a significant reduction in PCR sensitivity using clotted blood samples, although the full extent of this requires validation in additional cases.

All PCR screening in this study was performed on clotted blood samples, using the residual sample following serological evaluation. These were the only diagnostic specimens available to the group in this instance. Given the evidence presented in figure 1, if clotted blood samples cannot provide a repeatable PCR-positive result for EP from a horse with active disease and acute clinical signs, then this has important implications for reported negative PCR results. Despite the screening data initially appearing consistent with results from comparable studies in other countries, the availability of primarily clotted blood samples in this study is likely to have significantly underestimated the number of *T equi* PCR-positive carrier animals in the sample set. This may also explain the complete absence of *B caballi* detection by PCR despite serological detection among the samples. Consequently, the authors recommend avoiding the use of clotted blood samples for PCR screening.

iii) *Low-titre serologically positive, PCR-negative samples*. Typically, these may simply represent previous disease exposure, although in the case of EP it could signify a latent carrier state that lacks sufficient circulating parasite for DNA detection. Alternatively, these could be serological false-positive results, an issue inherent with serological testing.[26] However, given the apparent reduction of PCR sensitivity in this study, no further interpretation can be made on these samples.

Another conspicuous finding of this study is the apparently low uptake of EP testing in horses in the UK following importation (table 2). Strikingly, only a single sample of 1097 submitted to APHA was for the purpose of determining EP status at time of importation to the UK, strongly suggesting that there is widespread lack of awareness or indifference to EP biosecurity within the UK veterinary and equine industries. The most common purpose cited for sample submission was pre-export testing. This implies that the main driver for EP screening is to meet mandatory requirements for foreign export and not clinical investigation, and highlights the more stringent EP biosecurity controls imposed by other non-endemic countries such as the USA, Australia, New Zealand and Japan.

In summary, this study shows that a small but important proportion of equids residing in the UK are seropositive for EP, and that parasite DNA is detectable in a further proportion of these. Given the diagnostic limitations imposed in this study, namely the use of remnant clotted material following serological testing, it is likely that piroplasmosis DNA is present in a higher proportion of UK equids than reported here. As it is known that carriers of EP may undergo disease recrudescence at times of co-infection, stress and immunosuppression, UK veterinary practitioners should be aware that EP should be a differential diagnosis for horses presenting with characteristic clinical signs in this country, which may include pyrexia, lethargy and evidence of haemolysis.

Although a detailed distribution of EP vector tick species within the UK is not fully known, the presence of equids positive for parasite DNA in tick-infested pasture should be considered a potential risk for disease transmission to co-grazing equids, and this requires assessment. The authors note that the factors of reduced

restrictions on international equine movement and an absence of any UK formal import screening for EP, coupled with the limitations of current testing methods, present a continued risk to the UK equine population and industry. This study suggests that a combined approach of serology and parasite DNA detection is required to provide the most efficacious EP screening protocol. It is also suggested that in the event of positive animals being identified in the UK, follow-up screening of co-grazing animals and ticks could be considered as a means of local and national disease surveillance. The authors believe that a change in attitude towards the disease and national EP biosecurity is required before endemic disease establishment creates a complex problem that is more difficult to resolve.

**Acknowledgements** The APHA and AHT are gratefully thanked for their help in providing access to samples and serology data. Permission for sample use in the study was obtained at the point of submission.

**Funding** The Horserace Betting Levy Board (HBLB) funded the cost of nested PCR screening, and RMC is supported by an HBLB research scholarship (VET/RS/254).

**Competing interests** None declared.



## References

1 Rothschild CM. Equine Piroplasmosis. *Journal of Equine Veterinary Science* 2013;33:497–508.
2 de Waal DT. Equine piroplasmosis: A review. *British Veterinary Journal* 1992;148:6–14.
3 Tamzali Y. Equine piroplasmosis: An updated review. *Equine Vet Educ* 2013;25:590–8.
4 Hailat NQ, Lafi SQ, al-Darraji AM, *et al*. Equine babesiosis associated with strenuous exercise: clinical and pathological studies in Jordan. *Vet Parasitol* 1997;69:1–8.
5 Allsopp MT, Lewis BD, Penzhorn BL. Molecular evidence for transplacental transmission of *Theileria equi* from carrier mares to their apparently healthy foals. *Vet Parasitol* 2007;148:130–6.
6 Lewis BD, Penzhorn BL, Volkmann DH. Could treatment of pregnant mares prevent abortions due to equine piroplasmosis? *J S Afr Vet Assoc* 1999;70:90–1.
7 Holbrook AA. Biology of equine piroplasmosis. *J Am Vet Med Assoc* 1969;155:453–4.
8 Schwint ON, Ueti MW, Palmer GH, *et al*. Imidocarb dipropionate clears persistent *Babesia caballi* infection with elimination of transmission potential. *Antimicrob Agents Chemother* 2009;53:4327–32.
9 Grause JF, Ueti MW, Nelson JT, *et al*. Efficacy of imidocarb dipropionate in eliminating *Theileria equi* from experimentally infected horses. *Vet J* 2013;196:541–6.
10 Barnett SF. Babesia of horses in Britain. *Vet Rec* 1974;95:346–7.
11 Scoles GA, Ueti MW. Vector ecology of equine piroplasmosis. *Annu Rev Entomol* 2015;60:561–80.
12 Medlock JM, Hansford KM, Vaux AGC, *et al*. Distribution of the tick *Dermacentor reticulatus* in the United Kingdom. *Med Vet Entomol* 2017;31:281–8.
13 Phipps LP, Del Mar Fernandez De Marco M, Hernández-Triana LM, *et al*. *Babesia canis* detected in dogs and associated ticks from Essex. *Vet Rec* 2016;178:243.3–4.
14 ANON. Equine piroplasmosis confirmed in Ireland. *Veterinary Record* 2009;165:333.
15 Butler CM, Sloet van Oldruitenborgh-Oosterbaan MM, Stout TA, *et al*. Prevalence of the causative agents of equine piroplasmosis in the South West of The Netherlands and the identification of two autochthonous clinical *Theileria equi* infections. *Vet J* 2012;193:381–5.
16 Guidi E, Pradier S, Lebert I, *et al*. Piroplasmosis in an endemic area: analysis of the risk factors and their implications in the control of Theileriosis and Babesiosis in horses. *Parasitol Res* 2015;114:71–83.
17 DEFRA (2017) Intra-union trade in registered equidae, equidae for breeding and production equidae for slaughter (Moving under Annex III of 2009/156/EC) Notes for Guidance of Official Veterinarians and Exporters. http://ahvla.defra.gov.uk/documents/traces/horses/equidae-for-bps-nfg5.pdf (Accessed 23 July 2018).
18 OIE (2016) Handbook for the management of High Health, High Performance Horses. http://www.oie.int/fileadmin/Home/eng/Our_scientific_expertise/docs/pdf/Chevaux/HHP_Handbook_December_2016_V3.pdf (Accessed 23 July 2018).
19 OIE (2018) WAHIS Interface: Disease timeline country information. http://www.oie.int/wahis_2/public/wahid.php/Countryinformation/Countrytimelines (Accessed 23 July 2018).
20 Ueti MW, Palmer GH, Scoles GA, *et al*. Persistently infected horses are reservoirs for intrastadial tick-borne transmission of the apicomplexan parasite *Babesia equi*. *Infect Immun* 2008;76:3525–9.
21 OIE (2008) Terrestrial manual, Volume 2 Chapter 2.5.8. Equine Piroplasmosis. http://www.oie.int/fileadmin/Home/fr/Health_standards/tahm/2.05.08_EQUINE_PIROPLASMOSIS.pdf (Accessed 23 July 2018).
22 Ueti MW, Mealey RH, Kappmeyer LS, *et al*. Re-emergence of the apicomplexan *Theileria equi* in the United States: elimination of persistent infection and transmission risk. *PLoS One* 2012;7:e44713.
23 Criado-Fornelio A, Martinez-Marcos A, Buling-Saraña A, *et al*. Molecular studies on Babesia, Theileria and Hepatozoon in southern Europe. Part I. Epizootiological aspects. *Vet Parasitol* 2003;113:189–201.
24 Oura CA, Bishop RP, Wampande EM, *et al*. Application of a reverse line blot assay to the study of haemoparasites in cattle in Uganda. *Int J Parasitol* 2004;34:603–13.
25 Sigg L, Gerber V, Gottstein B, *et al*. Seroprevalence of *Babesia caballi* and *Theileria equi* in the Swiss horse population. *Parasitol Int* 2010;59:313–7.
26 Alanazi AD, Said AE, Morin-Adeline V, *et al*. Quantitative PCR detection of *Theileria equi* using laboratory workflows to detect asymptomatic persistently infected horses. *Vet Parasitol* 2014;206:138–45.
27 Tenter AM, Friedhoff KT. Serodiagnosis of experimental and natural *Babesia equi* and *B. caballi* infections. *Vet Parasitol* 1986;20:49–61.
28 Short MA, Clark CK, Harvey JW, *et al*. Outbreak of equine piroplasmosis in Florida. *J Am Vet Med Assoc* 2012;240:588–95.
29 Piantedosi D, D'Alessio N, Di Loria A, *et al*. Seroprevalence and risk factors associated with *Babesia caballi* and *Theileria equi* infections in donkeys from Southern Italy. *Vet J* 2014;202:578–82.
30 Rosales R, Rangel-Rivas A, Escalona A, *et al*. Detection of *Theileria equi* and *Babesia caballi* infections in Venezuelan horses using Competitive-Inhibition ELISA and PCR. *Vet Parasitol* 2013;196:37–43.
31 Bhoora R, Quan M, Matjila PT, *et al*. Sequence heterogeneity in the equi merozoite antigen gene (ema-1) of *Theileria equi* and development of an ema-1-specific TaqMan MGB assay for the detection of *T. equi*. *Vet Parasitol* 2010;172:33–45.